{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-104317","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-09-29T12:00:30+00:00","discovered_at":"2026-09-29T12:05:00.245006+00:00","generated_at":"2026-10-12T13:42:16.407351+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Allarity expands in-house lab to proteomics and cell line research, citing no cash-runway impact","bullets":["In-house medical laboratory adds proteomics and cell line research, building on existing transcriptomics work and CLIA clinical testing services.","nCounter Pro instrument now also runs the nCounter Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets.","Company says the expansion will not affect its current cash runway and may generate cost efficiencies by enabling more research in-house.","CEO Thomas Jensen: broader molecular insights support stenoparib (2X-121), a dual PARP and WNT pathway inhibitor in Phase 2 development.","New capabilities broaden the research services Allarity can offer to existing and prospective external partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-104317","json":"https://secwatch.observer/filing/0001213900-26-104317.json","markdown":"https://secwatch.observer/filing/0001213900-26-104317.md","text":"https://secwatch.observer/filing/0001213900-26-104317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/0001213900-26-104317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026104317/ea0306873-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:42:16.407351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}